Stockreport

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia [Yahoo! Finance]

Larimar Therapeutics, Inc.  (LRMR) 
PDF Frataxin data and safety data from the OLE study are intended to help support a potential Biologics License Application (“BLA”) submission for accelerated approval targ [Read more]